MXCT News Coverage — MaxCyte, Inc.

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte's SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs).

Aug 19, 2026 04:05 AM • globenewswire.com

MaxCyte Q2 Earnings Call Highlights

MaxCyte NASDAQ: MXCT reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectations and represented progress toward stabilizing the business before returning to growth in the second half of the year.

Aug 12, 2026 05:05 PM • marketbeat.com

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

Aug 12, 2026 04:17 PM • seekingalpha.com

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.12 per share a year ago.

Aug 12, 2026 03:16 PM • zacks.com

MaxCyte Reports Second Quarter 2026 Financial Results

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $5.5 million of common stock to date under the Company's $10 million share repurchase program authorized by the Board Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2026 financial results and reiterated its 2026 guidance.

Aug 12, 2026 12:05 PM • globenewswire.com

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.

Jul 21, 2026 04:05 AM • globenewswire.com

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2026 after the U.S. market close on Wednesday, August 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Jul 15, 2026 12:05 PM • globenewswire.com

VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering

ROCKVILLE, Md. & CHICAGO--(BUSINESS WIRE)-- #BioTechNews--VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced a strategic partnership focused on co-developing a new gene delivery solution using VectorBuilder's proprietary MiniVec™ plasmid system and MaxCyte's world-class clinical.

Jun 23, 2026 05:00 AM • businesswire.com

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

May 12, 2026 10:01 PM • seekingalpha.com

MaxCyte Q1 Earnings Call Highlights

MaxCyte NASDAQ: MXCT reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the decline.

May 12, 2026 05:09 PM • marketbeat.com

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.

May 12, 2026 02:40 PM • zacks.com

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte's Board authorized a $10 million share repurchase program ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results and reiterated its 2026 guidance.

May 12, 2026 12:05 PM • globenewswire.com

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Apr 29, 2026 12:05 PM • globenewswire.com

MaxCyte, Inc. (NASDAQ:MXCT) Receives $5.50 Average Price Target from Analysts

MaxCyte, Inc. (NASDAQ: MXCT - Get Free Report) has been assigned a consensus rating of "Hold" from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company.

Apr 23, 2026 11:46 PM • defenseworld.net

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte's common stock and a service-based restricted stock unit (“RSU”) award with respect to 187,500 shares of MaxCyte's common stock to Parmeet Ahuja in connection with his appointment as Chief Financial Officer of MaxCyte.

Mar 31, 2026 12:05 PM • globenewswire.com

MaxCyte Q4 Earnings Call Highlights

MaxCyte (NASDAQ: MXCT) executives told investors the company made "meaningful progress" in 2025 despite a difficult operating environment, highlighting continued strategic platform license (SPL) activity, integration of the SeQure Dx acquisition, cost restructuring, and the February launch of a new research-focused electroporation system. Management also provided 2026 revenue guidance that reflects ongoing headwinds in the first

Mar 25, 2026 11:07 PM • defenseworld.net

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

Mar 24, 2026 10:14 PM • seekingalpha.com

MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.1 per share a year ago.

Mar 24, 2026 02:37 PM • zacks.com

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in t otal cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md.

Mar 24, 2026 12:05 PM • globenewswire.com

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025.

Mar 23, 2026 04:05 AM • globenewswire.com

MXCT - MaxCyte, Inc.

Stock News